Articular manifestations in patients with inflammatory bowel disease treated with vedolizumab. (7th April 2020)

• Record Type: Journal Article
• Authors: Dupré, Anastasia; Collins, Michael; Nocturne, Gaétane; Carbonnel, Franck; Mariette, Xavier; Seror, Raphaèle
• Is Part Of: Rheumatology. Volume 59:Number 11(2020)
• Page Start: 3275
• Page End: 3283
• Publication Date: 2020-04-07
• Subjects: spondyloarthritis -- vedolizumab -- ulcerative colitis -- Crohn's disease; Rheumatism -- Periodicals; Rheumatology -- Periodicals; 616.723005
• DOI: 10.1093/rheumatology/keaa107
• Languages: English
• ISSNs: 1462-0324

Abstract

Abstract: Objective: Vedolizumab (VDZ) has been incriminated in the occurrence of articular manifestations in patients with inflammatory bowel diseases (IBDs). The aim of this study was to describe musculoskeletal manifestations occurring in IBD patients treated by VDZ and to identify risk factors. Methods: In this retrospective monocentric study, we included all consecutive patients treated by VDZ for IBD in our hospital. Incident musculoskeletal manifestations occurring during VDZ treatment were analysed and characteristics of patients with and without articular inflammatory manifestations were compared. Results: Between 2013 and 2017, 112 patients were treated with VDZ for IBD: ulcerative colitis ( n = 59), Crohn's disease ( n = 49) and undetermined colitis ( n = 4). Four patients (3.6%) had a history of SpA, whereas 13 (11.6%) had a history of peripheral arthralgia. Some 102 (91.1%) patients had previously received anti-TNF. After a mean (S.d .) follow-up of 11.4 (8.6) months, 32 (28.6%) patients presented 35 musculoskeletal manifestations, of which 18 were mechanical and 17 inflammatory. Among the latter, 11 had axial or peripheral SpA, 5 had early reversible arthralgia and 1 had chondrocalcinosis ( n = 1). Among the 11 SpA patients, only 3 (2.6%) had inactive IBD and may be considered as paradoxical SpA. The only factor associated with occurrence of inflammatory manifestations was history of inflammatory articular manifestation [7/16 (43.8%) vs 10/80 (12.5%), P = 0.007]. Conclusion: Musculoskeletal manifestations occurred in almost 30% of IBD patients treated with VDZ, but only half of them were inflammatory. Since most of the patients previously received anti-TNF, occurrence of inflammatory articular manifestations might rather be linked to anti-TNF discontinuation than to VDZ itself.